Clinical Trial Update: Study on BI 54903 (Inhaled Corticosteroid) Administered Once Daily or Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Short Acting Beta-2 Agonist (SABA) Therapy Alone [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating BI 54903 inhaled corticosteroid given once daily or twice daily via Respimat in asthma patients inadequately controlled on SABA was w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• BI 54903

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Asthma | Phase 2 | Status: WITHDRAWN